AstraZeneca 1st-qtr results beat estimates — but concerns over loss of Crestor patent remain

29 April 2016

A growth in total revenue driven by selling or out-licensing non-core products, could not prevent core operating profit for the first quarter of 2016 to decline at pharma major AstraZeneca (LSE: AZN).

It was a mixed set of results for the Anglo-Swedish firm, with the $6.12 billion total generated in revenue beating analysts’ predictions by 2.8% and 5% higher than in the first three months of 2015, but core operating profit and earnings per share (EPS) were down 12% compared to a year ago.

Core EPS dropped from $1.08 to $0.95 and the core operating profit reduced by $212 million to $1.59 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK